Jyong Biotech Ltd. (NASDAQ:MENS) Sees Significant Decrease in Short Interest

Key Points

• Short interest fell 18.9% to 234,254 shares as of March 31, equal to about 0.3% of the stock and a short-interest ratio of 1.2 days based on average volume.
• Shares traded down 1.5% to $2.59 with 100,408 shares changing hands, notable given a 52-week range of $1.43–$67 and 50-day/200-day moving averages of $2.15 and $17.86, respectively.
• Market sentiment is negative with Weiss Ratings reaffirming a "sell (e+)" and an average MarketBeat rating of "Sell," even as several institutional investors (including Geode, Millennium, BNP Paribas and Man Group) added or initiated positions.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totaling 234,254 shares, a decline of 18.9% from the March 15th total of 288,865 shares. Currently, 0.3% of the company's stock are sold short. Based on an average trading volume of 201,892 shares, the short-interest ratio is presently 1.2 days.

Jyong Biotech Trading Down 1.5%

Shares of Jyong Biotech stock traded down $0.04 on Thursday, reaching $2.59. 100,408 shares of the company were exchanged, compared to its average volume of 139,842. Jyong Biotech has a one year low of $1.43 and a one year high of $67.00. The company has a 50-day moving average of $2.15 and a 200 day moving average of $17.86.

Jyong Biotech (NASDAQ:MENS - Get Free Report) last announced its quarterly earnings data on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Jyong Biotech presently has an average rating of "Sell".

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MENS. BNP Paribas Financial Markets acquired a new stake in shares of Jyong Biotech during the 3rd quarter worth $67,000. Geode Capital Management LLC lifted its position in shares of Jyong Biotech by 19.6% during the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company's stock worth $254,000 after buying an additional 10,538 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Jyong Biotech during the 4th quarter worth $49,000. Millennium Management LLC bought a new stake in shares of Jyong Biotech during the 3rd quarter worth $512,000. Finally, Man Group plc bought a new stake in shares of Jyong Biotech during the 4th quarter worth $56,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.